First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

Köhne, CH; Hofheinz, R; Mineur, L; Letocha, H; Greil, R; Thaler, J; Fernebro, E; Gamelin, E; Decosta, L; Karthaus, M; J Cancer Res Clin Oncol. 2012; 138(1):65-72

Novel treatment avenues for peripheral T-cell lymphomas.

Hopfinger, G; Griessl, R; Sifft, E; Taylor, N; Kenner, L; Greil, R; Merkel, O; Expert Opin Drug Discov. 2012; 7(12):1149-1163

GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer

Rick, FG; Seitz, S; Schally, AV; Szalontay, L; Krishan, A; Datz, C; Stadlmayr, A; Buchholz, S; Block, NL; Hohla, F CELL CYCLE. 2012; 11(22): 4203-4210.

LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.

Schimanski, CC; Möhler, M; Schön, M; van Cutsem, E; Greil, R; Bechstein, WO; Hegewisch-Becker, S; von Wichert, G; Vöhringer, M; Heike, M; Heinemann, V; Peeters, M; Kanzler, S; Kasper, S; Overkamp, F; Schröder, J; Seehofer, D; Kullmann, F; Linz, B; Schmidtmann, I; Smith-Machnow, V; Gockel, I; Lang, H; Galle, PR; BMC Cancer. 2012; 12:144

Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.

Rick, FG; Schally, AV; Szalontay, L; Block, NL; Szepeshazi, K; Nadji, M; Zarandi, M; Hohla, F; Buchholz, S; Seitz, S; Proc Natl Acad Sci U S A. 2012; 109(5):1655-1660

What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?

Auberger, J; Greil, R; Lass-Flörl, C; Expert Rev Anti Infect Ther. 2012; 10(11):1229-1231

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Palumbo, A; Hajek, R; Delforge, M; Kropff, M; Petrucci, MT; Catalano, J; Gisslinger, H; Wiktor-Jędrzejczak, W; Zodelava, M; Weisel, K; Cascavilla, N; Iosava, G; Cavo, M; Kloczko, J; Bladé, J; Beksac, M; Spicka, I; Plesner, T; Radke, J; Langer, C; Ben Yehuda, D; Corso, A; Herbein, L; Yu, Z; Mei, J; Jacques, C; Dimopoulos, MA; N Engl J Med. 2012; 366(19):175-169

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

Jäger, U; Fridrik, M; Zeitlinger, M; Heintel, D; Hopfinger, G; Burgstaller, S; Mannhalter, C; Oberaigner, W; Porpaczy, E; Skrabs, C; Einberger, C; Drach, J; Raderer, M; Gaiger, A; Putman, M; Greil, R; Haematologica. 2012; 97(9):1431-1438

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.

Lang, I; Inbar, MJ; Kahán, Z; Greil, R; Beslija, S; Stemmer, SM; Kaufman, B; Zvirbule, Z; Steger, GG; Messinger, D; Brodowicz, T; Zielinski, C; Eur J Cancer. 2012; 48(17):3140-3149

Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.

Merkel, O; Wacht, N; Sifft, E; Melchardt, T; Hamacher, F; Kocher, T; Denk, U; Hofbauer, JP; Egle, A; Scheideler, M; Schlederer, M; Steurer, M; Kenner, L; Greil, R; Leukemia. 2012; 26(12):2508-2516